• Overview
    • Solid Tumor
    • Blood Cancer
    • Physicians
    • • Jiahui International Cancer Center (JICC), affiliated with Shanghai Jiahui International Hospital, has a close strategic collaboration with Massachusetts General Hospital and its cancer center. Jiahui International Cancer Center represents the cutting edge of international oncology, providing patients over the age of 14 with fast, comprehensive, international-standard diagnosis and treatment.
      • Jiahui International Cancer provides advanced diagnosis and treatment methods, meticulous and holistic care, thorough communication, an approach that places the needs of you and your family at the core, comprehensive support, a safe and comfortable environment, and professional follow-up care.

      CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a major breakthrough in personalized cellular immunotherapy for cancer. The process involves the collection of the patient's T-cells, after which in vitro genetic engineering modifications of T-cells are made to enhance the T-cells' ability to specifically recognize cancers. These modified T-cells (i.e., CAR-T cells) are then infused back to the patient. The treatment enables the accurate killing of cancer cells and the formation of memory T-cells that fight the cancer in the long term and ensure a more sustainable remission.

      Currently, CAR-T therapy has been approved in China for the treatment of lymphoma and multiple myeloma. CAR-T therapy is individualized in nature and involves many key aspects such as patient screening, bridging therapy, adverse reaction management, and long-term follow-ups.

      Jiahui’s CAR-T multidisciplinary treatment team, led by Dr. Vicky LEE, Director of the Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, has been doing a series of explorations in the clinical practice of novel concepts and technologies, aiming to bring hope and new treatments to more patients with blood cancers.


      JIAHUI News | Jiahui's New CAR-T Cancer Treatment a Success



      ● Outpatient reception hours: Monday to Saturday 9:00-18:00 (excluding national holidays)
      ● Inpatient service hours: Available 24/7 (year-round)
      ● In order to get in touch with us via WeChat, please scan the this QR code:


      ● Scan the QR code below to download the Jiahui Health APP:



      Our Advantages

      Jiahui International Cancer Center provides accurate, comprehensive, and patient-centered one-stop services, including cancer screening, diagnosis, radiotherapy, chemotherapy, targeted therapy, immunotherapy, CAR-T therapy, comprehensive surgical services, cancer support services, cancer risk assessments, and patient education, as well as a patient-centered medical treatment process to help patients and their families save valuable time and energy. Jiahui International Cancer Center offers the following core advantages:


      International-standard Healthcare

      • A close strategic collaboration with Massachusetts General Hospital and its cancer center.
      • Led by a number of international oncology experts with a multidisciplinary team made up of core departments including Medical Oncology, Surgical Oncology, and Radiation Therapy.
      • Hour-long initial consultations, allowing patients ample consultation time.
      • Following the Tumor Board System to decide individualized treatment plans.
      • An international approach to patient privacy, safety, medical care, patient experience, etc.


      Collaborative Innovation

      • Rapid introduction and active use of new oncology drugs, advanced technologies, and cutting-edge solutions.
      • In-depth collaborations with numerous local tertiary hospitals and expert teams to share high-quality medical resources and create joint diagnosis and treatment channels between Jiahui and other hospitals.
      • A "vomit-free + pain-free + optimal nutrition" approach to cancer symptom management and cancer palliative care, integrating patient-centered care throughout the entire process.


      Time Efficient Processes

      • Rapid treatment provided for cancer patients at all stages, including emergency, severe, and terminal cancer patients.
      • Same-day hospitalization, with the first radiation therapy/chemotherapy session occurring within two working days, and surgery can be arranged within one week, thereby optimizing treatment success.
      • Medical insurance payments supported (including critical illness insurance, direct settlement, etc.) as well as commercial insurance payments, with direct payments from over 50 global mainstream insurance providers, ensuring efficient and convenient payment processes.

        • Jiahui International Cancer Center’s core commitment is to provide patients with excellent oncology treatment solutions. Currently, we provide one-stop cancer care with the following key treatments and services available:

        • Surgery
        • Chemotherapy
        • Targeted Therapy
        • Immunotherapy
        • CAR-T Cell Therapy
        • Precision radiotherapy, e.g., SBRT
        • Interventional therapy, e.g., HAIC, TACE
        • Genetic testing
        • Cancer palliative care
        • Autologous hematopoietic stem cell transplantation
        • Specialty clinics (cancer pain management clinic, cancer genetics clinic, etc.)
        • Inpatient care (palliative care, nutritional management, tumor complication management, symptom management, etc.)
        • Nursing care, such as PICC, PORT
        • Medical imaging, e.g., ultrasound, CT, MRI
        • Endoscopy, e.g., gastroscopy, enteroscopy
        • Laboratory tests (for blood, urine, other body fluids or tissue samples)
        • Others: MDT consultation, international teleconsultation, and medical consultation services


      Core service 1:
      Multidisciplinary Consultation Services
      Over the past two decades, Multi-Disciplinary Team (MDT) consultations have become standard within cancer treatment approaches in Western countries. The multidisciplinary consultation model aims to help patients avoid moving between different medical departments, experiencing different medical opinions, etc. Cancer treatment requires a long-term approach, and should be based on various factors, including the patient’s condition, quality of life, etc., and in most cases requires a combination of treatments, including surgery, chemotherapy, immunotherapy, targeted therapy, radiation therapy, etc.

      The multidisciplinary team at Jiahui International Cancer Center is composed of physicians from different departments, including Medical Oncology, Surgical Oncology, Radiation Therapy, Pathology, Medical Imaging, Mental Health, as well as Oncology Nurses, Rehabilitation Therapists, Genetic Counselors, and Nutritionists. The team focuses on each case to jointly develop an integrated comprehensive diagnosis and treatment plan based on their extensive experience and professional opinions, the necessity of treatment, treatment risks, treatment sequence, follow-up details, etc.

      Jiahui’s Multidisciplinary Consultation Service aims to:
      • Provide comprehensive diagnosis and treatment plans that are in line with evidence-based medicine and international standards.
      • Improve the patient's medical experience, helping them to avoid repeated visits, and save unnecessary expenses.
      • Promote patient continuity of care.




      Core Service 2:
      Systemic Cancer Therapy
      The Medical Oncologists at Jiahui International Cancer Center develop personalized systemic treatment plans. Cancer treatments such as chemotherapy, immunotherapy, targeted therapy, and CAR-T therapy significantly improve the cure rate, promote quality of life, and prolong the life of cancer patients [1]. However, it is important to note that cancer treatments may have side effects, the majority of which are controllable and reversible. Jiahui’s Medical Oncologists have extensive experience in cancer treatment and drug safety management, and provide patients with services such as drug assessments, safety monitoring, and symptom management informed by international standards and based on the patient’s specific conditions.

      Core Service 3:
      Radiation Therapy
      The National Cancer Institute (NCI) highlights that today's advanced approach to radiation therapy can improve the accuracy of treatment while greatly reducing the impact on normal tissue around the tumor.

      The Radiation Therapy Department of Jiahui International Cancer Center is equipped with a Versa HD medical linear accelerator, which can carry out volumetric intensity-modulated radiation therapy (VMAT), intensity-modulated radiation therapy (IMRT), stereotactic body radian therapy (SBRT), surface-guided radiation therapy (SGRT), image-guided radiation therapy (IGRT), HYPO and other cutting-edge radiation therapy technologies to provide patients with high-quality radiation therapy services.

      Specialized Service 1
      CAR-T Program
      CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a major breakthrough in personalized cellular immunotherapy for cancer. The process involves the collection of the patient's T-cells, after which in vitro genetic engineering modifications of T-cells are made to enhance the T-cells' ability to specifically recognize cancers. These modified T-cells (i.e., CAR-T cells) are then infused back to the patient. The treatment enables the accurate killing of cancer cells and the formation of memory T-cells that fight cancer in the long term and ensure a more sustainable remission.

      Currently, CAR-T therapy has been approved in China for the treatment of lymphoma , multiple myeloma and acute lymphoblastic leukemia. CAR-T therapy is individualized in nature and involves many key aspects such as patient screening, bridging therapy, adverse reaction management, and long-term follow-ups.

      Jiahui’s CAR-T therapy program include outpatient consultations, screenings and evaluations, T-cell collection, CAR-T cell infusion, adverse reaction monitoring and management, etc. The services are spearheaded by Jiahui International Cancer Center and combine various departments, including Cardiovascular Medicine, Neurology, ICU, Pulmonology, Gastroenterology, Nephrology, Medical Imaging, Laboratory, Pharmacy, etc., as well as the cancer center nursing team to form a comprehensive CAR-T treatment system.

      The professional clinical team is connected to an international diagnosis and treatment platform and local high-quality medical resources in Shanghai. Jiahui International Cancer Center has completed multiple CAR-T training certifications and has been authorized to carry out clinical applications of CAR-T therapy. The hospital is equipped with advanced T-cell extraction equipment and a dedicated CAR-T ward, allowing for comprehensive monitoring and ensuring patient comfort.

      The cost of CAR-T therapy is predominantly made up of drug expenses and non-drug expenses. The total treatment cost for this therapy in China is significantly lower than in the United States and in European countries. Payment for the CAR-T therapy program at Jiahui International Cancer Center can be settled through commercial insurance or self-pay.

      Specialized Service 2:
      Remote Consultation Services (Written/Video) and Medical Services

      For cases with rare or complex conditions, or where patients and families would like to understand other diagnosis and treatment options, Jiahui offers remote oncology consultation services with expert physicians abroad.

      Our remote consultation service aims to provide convenient and efficient solutions for people who need to consult with professional doctors abroad. Through written or video conferencing, we connect doctors and patients for remote medical consultations.

      This service currently covers high-quality medical resources and oncologist databases in many different countries, predominantly in the United States and Japan. Other particular countries, medical institutions, and doctors can be determined according to your specific diagnosis and condition.

      After the consultation, the doctors at Jiahui International Hospital can arrange on-site treatment, based on the treatment suggestions and the patient’s situation. If referrals abroad are required, Jiahui’s International Office can assist in facilitating global medical services.

      Specialized Service 3:
      Cancer Genetic Clinic (Cancer Risk Assessment)
      Cancer is a disease with a genetic predisposition. This means that inherited susceptibility genes are passed down in families, with family members who inherit the mutation being at higher risk of developing the corresponding cancer.

      By sequencing a person’s genes in their blood, body fluid, or tissue samples and testing the cancer gene profile, it can be determined whether that person carries a susceptible gene for a certain form of cancer. This is helpful for identifying the risk for certain cancers early and can offer guidance regarding cancer treatment for cancer patients.

      Jiahui’s Cancer Genetic Clinic is led by a professional physician licensed in cancer genetic risk assessment. It provides cancer genetic counseling and cancer risk assessment services to cancer patients or those with a history of cancer, as well as those with a family history of cancer. The Cancer Genetic Clinic offers the following services:

      • Pre-cancer genetic testing consultations: A physician will determine your personal and family cancer history, assess your family health history, discuss your risk of hereditary cancer, and offer screening and management recommendations for high-risk individuals. The appropriate assessment, screening, or genetic testing will be determined based on your personal situation.
      • Consultation after cancer genetic testing: A physician will interpret the genetic report to provide you and your family members with useful information about cancer risk. Based on the analysis of the test results, the physician will provide recommendations and guidance on cancer screening, prevention, and cancer treatment medication.

      References
      [1] Zhang Yiran, Jin Wenmin. Current status and development of medical oncology treatment [J]. Chinese Journal of Oncology Prevention and Treatment, 2018, 25(S1): 311-312.

      Optimal Care Environment and Advanced Equipment
      Our medical facility boasts a private and elegant environment equipped with state-of-the-art software and hardware. Designed to replicate the warmth and comfort of home, the Jiahui International Cancer Center leverages its international medical team and cutting-edge technology to deliver comprehensive medical services to patients.

      The inpatient department of JICC offers over 50 single rooms, ensuring a personalized and comfortable experience. Additionally, our outpatient department features dedicated daytime infusion rooms, providing flexibility to cater to the diverse care needs of patients and their families.

      • Outpatient reception desk
      • Relaxation area
      • Daytime infusion room
      • Single inpatient wards as well as negative pressure wards and CAR-T dedicated isolation wards (equipped with laminar flow beds)
      • Radiation therapy equipment


      · Reception & Relaxation Area 





      · Day Infusion Unit



      · Inpatient ward (all single rooms), including negative pressure wards and a dedicated isolation ward for CAR-T therapy (equipped with laminar flow beds)

      · Medical equipment

    • Jiahui International Cancer Center provides diagnosis and treatment for solid tumors at all stages (including advanced and terminal cancer patients):

      • Hepatobiliary and pancreatic tumors (liver cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, etc.)
      • Gastrointestinal tumors (stomach cancer, colorectal cancer, etc.)
      • Breast cancer
      • Lung cancer
      • Urological tumors (bladder cancer, prostate cancer, kidney cancer, adrenal gland tumors, etc.)
      • Gynecological tumors (cervical cancer, endometrial cancer, ovarian cancer, etc.)
      • Esophageal cancer
      • Brain glioma
      • Head and neck tumors (nasopharyngeal cancer, laryngeal cancer, thyroid cancer)
      • Other tumors (sarcoma, melanoma, etc.)

      Solid Tumor Specializations

      • Gastrointestinal tumors
      Jiahui International Cancer Center specializes in the diagnosis and treatment of hepatobiliary and pancreatic cancers, particularly liver cancer, cholangiocarcinoma, pancreatic cancer, gallbladder cancer, etc., as well as gastrointestinal tumors, particularly gastric cancer, intestinal cancer, etc. The services are led by an international multidisciplinary team leveraging advanced technology, innovative medication regimens, SBRT precision radiation therapy, and HAIC/TACE treatments. Novel technologies, such as electronic gastrointestinal endoscopy system fluorescence laparoscopy, gastrointestinal endoscopy, laparoscopic microscopy, and a range of surgical options ensure patients have access to international standard cancer diagnosis and treatments.

      • Breast cancer
      Equipped with a multidisciplinary team led by international breast cancer experts, Jiahui provides breast health screening, breast cancer diagnosis, comprehensive breast cancer treatment, and individualized treatment plans.

      Our patient-centered breast cancer treatment approach takes both health and cosmetic considerations into account. We offer complex breast-conserving techniques, breast reconstruction, and other surgeries, and carry out breast-conserving postoperative radiation therapy.

      Radiation therapy can be completed within three weeks, and for all patients requiring radiation therapy on the left breast, the deep inspiration breath-holding (DIBH) technique is used to protect the heart. Customized cancer genetic screening packages and individualized consultations are provided for families at a high risk of breast cancer.

      • Lung cancer
      Jiahui International Cancer Center collaborates with various departments within Jiahui, including Oncology and Pulmonology as well as a number of leading domestic tertiary hospitals. Leveraging a multidisciplinary system, Jiahui International Cancer Center provides pulmonary nodule screening, lung cancer differential diagnosis, one-stop comprehensive treatment services (including surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, etc.), and develops personalized diagnosis and treatment plans in line with international standards that meet the patient's specific needs.

      Due to the increased prevalence of cancer among relatives of lung cancer patients, we offer customized cancer genetic screening packages and individualized consultations for families with a high risk of lung cancer.

      State-of-the-art Equipment


      Jiahui International Cancer Center boasts state-of-the-art imaging facilities tailored to effectively address diverse tumor types. Our arsenal includes a 3.0T MRI simulation positioning machine, a large-diameter 4D-CT simulation positioning machine, a respiratory gating system, an optical body surface tracking system, and a medical linear accelerator equipped with a six-dimensional bed, among other cutting-edge instruments. These resources furnish robust support for treatment endeavors.

      Our commitment to precision begins with MRI-guided precise positioning and target delineation, ensuring millimeter-level accuracy in radiotherapy delivery. Rigorous machine quality control protocols are implemented at every stage to minimize errors, thereby mitigating treatment-related side effects and adverse outcomes. Stringent quality control measures encompass all facets of radiotherapy administration.

      Moreover, we tailor-make various styles of fixed molds in response to clinical requirements, providing patients with precise protection while enhancing their comfort throughout treatment.

    • Blood cancer: Lymphoma, myeloma, leukemia

      Our Hematology Oncology team are a member of the Shanghai Ruijin Hematology Medical Alliance and have established in-depth collaborations with a number of comprehensive tertiary hospitals in Shanghai that specialize in the diagnosis and treatment of hematological diseases. This allows for the sharing of high-quality medical resources and the two-way management of patients.

      Our center is fitted with specialized equipment for patients with hematological tumors and enables the rapid introduction of new drugs, novel technologies, and advanced therapies, including targeted new drugs; CAR-T cell therapy; autologous stem cell collection and reinfusion therapy using the industry-leading Spectra Optia system; etc. The inpatient department is equipped with single wards, negative pressure wards, and CAR-T dedicated isolation wards (equipped with laminar flow beds), reducing infection risks and ensuring the safety of patients with hematological tumors.


      CAR-T Therapy
      CAR-T therapy, or chimeric antigen receptor T-cell therapy, is a major breakthrough in personalized cellular immunotherapy for cancer. The process involves the collection of the patient's T-cells, after which in vitro genetic engineering modifications of T-cells are made to enhance the T-cells' ability to specifically recognize cancers. These modified T-cells (i.e., CAR-T cells) are then infused back to the patient. The treatment enables the accurate killing of cancer cells and the formation of memory T-cells that fight the cancer in the long term and ensure a more sustainable remission.

      Currently, CAR-T therapy has been approved in China for the treatment of lymphoma and multiple myeloma. CAR-T therapy is individualized in nature and involves many key aspects such as patient screening, bridging therapy, adverse reaction management, and long-term follow-ups.

      Jiahui’s CAR-T multidisciplinary treatment team, led by Dr. Vicky LEE, Director of the Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, has been doing a series of explorations in the clinical practice of novel concepts and technologies, aiming to bring hope and new treatments to more patients with blood cancers.

      CAR-T Team
      Drawing from international CAR-T clinical guidelines, Jiahui International Cancer Center has meticulously developed a standardized service process and quality control system to safeguard the personalized treatment of patients. The CAR-T treatment, led by Dr. Vicky Lee from the Department of Hematology, required strong collaborations with multiple specialties and departments across Jiahui, including Cardiology, Neurology, ICU, Pulmonology, Gastroenterology, Nephrology, Medical Imaging, Laboratory, Pharmacy, and various other departments. The nursing team from Jiahui International Cancer Center collaborated to conduct multiple training sessions and scenario simulations in the CAR-T treatment reparation, with the aim of staying up-to-date with the patient's evolving condition in a timely manner.

      Complementing our experts, the hospital is equipped with cutting-edge T cell extraction equipment and CAR-T-dedicated wards, ensuring comprehensive patient monitoring and providing a comfortable treatment experience. Our commitment to both hardware and software facets guarantees optimal care and support throughout the CAR-T therapy journey.

      CAR-T News
      First Myeloma Patient Treated with CAR-T Successfully Discharged
      Jiahui's New CAR-T Cancer Treatment a Success

      How to contact us?
      Wechat Contact:


      Email Contact:
      cancerhub@jiahui.com

    • Languages

      Location

      Specialty

      Doctors

      Vicky LEE, MD, PhD

      Department:
      Medical Oncology
      Palliative Care
      Genetic counseling
      Cancer Pain Management Clinic
      Cancer Gentic Clinic
      Medical Oncology(Solid Tumor)
      Medical Oncology (Hematology)
      International Cancer Consultant
      Cancer Center (Follow-up Consultation Only)
      Hepatobiliary Tumor MDT Clinic
      Colorectal Tumor MDT Clinic
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Vicky LEE, MD, PhD is Director of Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, and she has over 30 years of experience in the cancer research and clinical care field. She is an internationally well-known expert in medical oncology, hematology and cancer risk assessment. Dr. LEE has worked 3 years for Peking University First Hospital, and then went to Kyoto University School of Medicine (Japan) and New York University School of Medicine (United States) for further study in breast cancer research and cancer immunology research. Before joining Jiahui Health, Dr. LEE worked in medical oncology for over 20 years in the United States. Since 1995 in US, she has been board certified in American Board of Internal Medicine (ABIM), American Board of Hematology and American Board of Medical Oncology. She received Certificate of Intensive Course in Cancer Genetic Risk Assessment at City of Hope in 2018. She also has Oregon State Medical License and Washington State Medical License.

      Dr. LEE is currently a board member of the Washington State Society of Medical Oncology (WSMOS), and is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the Oregon Society of Medical Oncology (OSMO).

      With solid knowledge and professional training in USA, clinical experience in treating cancer patients, Dr. LEE is familiar with advanced international techniques in cancer prevention, diagnosis and treatment. She is skilled in the treatment of rare and complex cancers, and is adept at communicating with patients and their families. Dr. Vicky LEE always encourages patients to participate in decision making of cancer treatment plan with doctors, as this will enhance patients’ understanding of the disease. Hence, they will corporate well with the treatment plan and achieve better outcome. Dr. LEE cares about patients’ quality of life and good at manage patients’ cancer pain through standardized and individualized treatment plans.

      Dr. LEE specializes in hematology and oncology treatment including but not limited to:

      · Treatment of solid tumor, special interest in breast cancer, melanoma, colon cancer, and lung cancer.
      · Management of blood tumors, especially in myeloma and lymphoma.
      · Diagnosis and treatment of benign hematological diseases involving antithrombotic therapy and management of myeloproliferative disorders, MDS.
      · Cancer Genetics consultation and cancer risk assessment.
      · Palliative Care and Management of cancer pain.

      Read More

      Andrew X. ZHU(External Specialist), MD, PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology
      Medical Oncology(Solid Tumor)
      International Cancer Consultant
      Hepatobiliary Tumor MDT Clinic
      Colorectal Tumor MDT Clinic
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Andrew X. ZHU, MD, PhD serves as a multi-site practice physician at Jiahui International Cancer Center. Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma(HCC) and cholangiocarcinoma, Dr. Zhu has served as a principle investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.


      Dr. Andrew X. Zhu is a founding board member of the International Liver Cancer Association(ILCA), Fellow of American College of Physicians (ACP), and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and former Professor of Medicine at Harvard Medical School.


      Dr. Andrew X. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009. The hepatobiliary cancer MDT included experts from Surgical Oncology, Transplant Surgery, Interventional Radiology, Radiation Oncology, Hepatology and Pathology. In addition, Dr. Andrew X. Zhu led a series of pivotal clinical studies in advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma(BTC) during his tenure as director of Liver Cancer Research at the Mass General Cancer Center. As the lead global principal investigator, he led the pivotal studies which led to the regulatory approval of pembrolizumab and ramucirumab in advanced HCC. As a co-principal investigator, he is lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations, which has met the primary endpoint. Under the leadership of Dr. Andrew X. Zhu, he and his team established the hepatocellular cancer treatment center in New England, USA, which has become one of the most active clinical research centers for liver cancer in the United States.

      Read More

      Lily ZHOU, MD, PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology
      Palliative Care
      Hematology
      Medical Oncology (Hematology)
      Cancer Center (Follow-up Consultation Only)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Lily ZHOU serves as Section Head of Hematology at Jiahui International Cancer Center. Dr. Zhou graduated from the Second Military Medical University in 2004 with Master of Medicine, and earned her PhD in the affiliated Shanghai Changzheng Hospital in 2007. During 2012 and 2014, she completed her post-doctoral work in the Hematology/Oncology Department of University of California, San Francisco (UCSF), US. Prior to joining Jiahui, Dr. Zhou served as an associate professor oncologist with an expertise in hematology at Shanghai Changzheng Hospital. Being a hematologist for more than ten years, and served a chief physician in hematology, she specializes in the diagnosis and treatment of myeloma, lymphoma and leukemia, as well as benign hematological disorders such as anemia, thrombocytopenia, coagulation dysfunction, etc.


      Dr. Zhou has successively presided over the projects funded by the Translational Medicine of Myeloma at UCSF, National Natural Science Foundation, Shanghai Thousand Talents program and the Myeloma Program of Chinese Medical Doctor Association. She has participated in several international multi-site clinical trials, as well as some national and civic trials. As a first author, she has published more than ten SCI papers.


      Dr. Zhou is a committee member of Hematology Society of shanghai medical association, translational hematology committee of the Shanghai medical association, and youth committee member of the hematology rehabilitation committee of the Chinese medical association, also a member of the American cancer association (ASCO), and a committee member of the experimental diagnostics and transplantation immunology group of the hematology branch of the Chinese medical association.

      Read More

      LI Ping (External Specialist), MD,PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English,  日本語
      Doctor's bio

      Dr. LI Ping serves as a Multi-site oncologist at Jiahui International Cancer Center and a chief physician in hematology in Shanghai Tongji Hospital, as well as a Professor and Doctoral Supervisor in Tongji University School of Medicine.


      Graduated from Soochow University Medical School in 1999, Dr. Li studied in Japan in 2003 and received her MD degree from Nagoya University in 2009. After graduating, she studied at the Aichi Oncology Hospital in Japan for more than three years and returned to China in 2012 to work at Shanghai Tongji Hospital.


      Dr. Li specializes in diagnosis and treatment of hematological malignancies such as leukemia, myeloma, and lymphoma, especially in study and clinic application of CAR-T cell therapy (with over 500 CAR-T treated patients) .


      Dr. Li is recently a youth committee member of the hematology branch of the Chinese medical association, a member of the lymphoma committee of the Chinese Anti-Cancer Association, a member of the committee of the blood immunity branch of the Chinese Society for Immunology, a member of the committee for biological therapy of the Chinese Research Hospital Association, a deputy director of youth committee member of the lymphoma committee of the Shanghai Anticancer association, a standing committee member of the hematology branch of the Shanghai Association of Chinese Integrative Medicine, and a member of the committee of the blood immunity branch of the Shanghai Society for Immunology.. She has presided over 2 projects funded by the National Natural Science Foundation of China (NSFC), and participated in many key R&D projects of the Ministry of Science and Technology, national projects and Shanghai Science and Technology Commission projects. She has published more than 30 papers, including more than 10 SCI papers as first author or corresponding author.

      Read More

      LI Junmin(External Specialist), MD, PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Li Junmin, MD, PhD, currently serves as the Director of the Hematology Department at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He holds the positions of vice president of the Hematology Branch of the Chinese Medical Doctor Association (CMDA), president of the Hematology Branch of the Chinese Geriatrics Society, chairman of the Shanghai Hematology Branch of the Chinese Medical Association (CMA), chairman of the Shanghai Hematology-Oncology Committee of the China Anti-Cancer Association, vice president of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and chief scientist of the tumor mRNA vaccine key project supported by the Ministry of Science and Technology.


      Pr. Li has been engaged in clinical and scientific research in the field of hematology in internal medicine for a long time. He has extensive experience in the pathogenesis and treatment of hematological malignancies and immune-related blood disorders. He has been the principal investigator for four projects funded by the National Natural Science Foundation and one key project of the Ministry of Science and Technology of the PRC. He has also successfully led an 863-Initiative research project and one special project sponsored by the Ministry of Health of the PRC. At the provincial and ministerial levels, he has undertaken five research projects, including those supported by the Ministry of Education of the PRC and the Shanghai municipality.


      Pr. Li has an impressive publication record, with nearly a hundred papers published in domestic and international academic journals. Among his accolades are the prestigious National Science and Technology Award, the Ministry of Education Scientific and Technological Achievement Award, the Shanghai Science and Technology Progress Award, and the Shanghai Medical Science and Technology Award. His expertise lies in the field of hematological malignancies, focusing on diseases affecting the blood system such as leukemia, lymphoma, multiple myeloma, and immune-related blood disorders like idiopathic thrombocytopenic purpura. 

      Read More

      HU Jiong(External Specialist), MD, PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Hu Jiong currently holds the positions of Deputy Director of the Hematology Department and Director of the Bone Marrow Transplantation (BMT) Unit at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Dr. Hu is a full member of the American Society of Hematology, serving on the Academic Committee of Myeloid Neoplasm. He is also a distinguished member of the Global Committee of the European Society for Blood and Marrow Transplantation (EBMT). In addition to his impressive affiliations, Dr. Hu serves as the vice president of the Shanghai Hematology Physicians Branch of the Chinese Medical Association, and the deputy director of the Shanghai Society for Transplant Immunology.


      Pr. Hu has contributed his expertise to the Hematology Department for adults at Saint-Louis Hospital in Paris, France, as well as the prestigious Bone Marrow Transplantation Center at Queen Mary Hospital, Hong Kong, China. In 2023, he successfully completed his postdoctoral research at the esteemed National Heart, Lung, and Blood Institute (NIH-NHLBI) in the United States.


      Pr. Hu has dedicated his career to advancing both basic and clinical research in the field of hematopoietic stem cell transplantation. His primary focus has been on optimizing clinical treatment systems and exploring drug resistance mechanisms and targeted reversal therapies in leukemia. His remarkable contributions include leading four projects funded by the prestigious National Natural Science Foundation, receiving a research grant from the Shanghai Outstanding Young Physician Program, and having published over 100 SCI papers.


      In recognition of his outstanding achievements, He has been awarded the second prize of the National Natural Science Award in 2016 (as the fourth contributor), the grand prize of the Shanghai Natural Science Award in 2015 (as the fourth contributor), and the 2022 EBMT Young Leader Award.

      Read More

      Vicky QI, MD, PhD

      Department:
      Jiahui International Cancer Center
      Medical Oncology
      Palliative Care
      Medical Oncology(Solid Tumor)
      Cancer Center (Follow-up Consultation Only)
      Hepatobiliary Tumor MDT Clinic
      Colorectal Tumor MDT Clinic
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Vicky QI is an oncologist at Jiahui International Cancer Center. Dr. Qi graduated from Shanghai Jiaotong University School of Medicine in 2012 with master’s degree in Respiratory Medicine, and earned her Ph.D. in Oncology in 2017 from Tongji University School of Medicine. During 2015 and 2016, she worked at M.D. Anderson Cancer Center as a visiting scientist. Before joining Jiahui Health, Dr. Qi served as a vice-chief physician in the Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University. Dr. Qi specializes in diagnosis and treatment of solid tumor, especially lung cancer. She also performed the operation of bronchoscopy and CT-guided transthoracic percutaneous fine needle aspiration and core biopsy. 


      As for scientific research, Dr. Qi has participated in several international and domestic multi-center clinical trials for anti-cancer drugs. She has presided over youth fund of national natural science foundation of China (NSFC) and has been involved in the research of drug resistance in lung cancer. As the first author, she has published more than 10 peer-reviewed papers in SCI Journals. 

      Read More

      WANG Hongzhe, MD

      Department:
      Medical Oncology
      Palliative Care
      Medical Oncology(Solid Tumor)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. WANG Hongzhe is currently an oncologist at Jiahui International Cancer Center. Dr. Wang graduated from Guangxi Medical University in 2008 with a Master's degree in Internal Medicine. After graduation, Dr. Wang has long been engaged in front-line clinical work and has participated in many clinical teaching and research exchanges with the Dana-Farber Cancer Institute (DFCI) in China. Dr. Wang insists on the principle of individualized treatment in the diagnosis and comprehensive medical treatment of common malignant tumors in medical oncology. He specializes in diagnosis and comprehensive treatment of malignant lymphoma, lung cancer, breast cancer and other malignant tumors.

      Read More

      MAO Aiqin, MD

      Department:
      Medical Oncology
      Palliative Care
      Medical Oncology(Solid Tumor)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话
      Doctor's bio

      Dr. MAO Aiqin is currently a medical oncologist at Jiahui International Cancer Center. She graduated from Xin Xiang Medical College with a bachelor's degree in 1997 and was engaged in teaching and clinical research of internal medicine at the affiliated Hospital of Henan Polytechnic University. In 2010, she received her master's degree in Clinical Oncology from Guang Xi Medical University. After graduation, she has been working in clinical practice and has rich knowledge in internal medicine and oncology.


      Before joining Jiahui, Dr. Mao served as the associate chief physician at the Third Ring Hospital of Cancer Hospital of Chinese Academy of Medical Sciences and the Department of Oncology of Boao Evergrande International Hospital. She has long been engaged in front-line clinical work in the department of oncology and has accumulated rich clinical experience. Dr. Mao specializes in standardized chemotherapy and palliative treatment of many cancer types, especially for precision personalized treatment for lung and breast cancer. She is also a highly responsible individual who is patient-centered.


      In terms of clinical research, Dr. Mao has participated in many clinical trials/projects and has published many clinical oncology-related papers.

      Read More

      DONG Yan, MD, PhD

      Department:
      Medical Oncology
      Palliative Care
      Hematology
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English,  日本語,  한국어
      Doctor's bio

      Dr. Dong Yan is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a bachelor’s degree in Clinical Medicine from Peking University Health Science Center in 2002 and received her Ph.D. from the Graduate School of Medicine at the University of Tokyo in 2008. Before joining Jiahui Health, Dr. Dong worked at Tongji Hospital in Shanghai.


      Dr. Dong has dedicated her career to clinical and research work in hematology. She is highly proficient in diagnosing and treating a wide range of common blood disorders, including various types of anemia, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), and thrombocytopenia. She has also accumulated clinical experience in advanced blood cancer therapies such as autologous stem cell transplantation, allogeneic hematopoietic stem cell transplantation, and CAR-T.


      Dr. Dong has published several papers in both domestic and international core journals and is currently a committee member of the Hematology Branch of Shanghai Medical Association(SMA).

      Read More

      Lisa FENG, MD

      Department:
      Medical Oncology
      Palliative Care
      Hematology
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. Lisa FENG is currently a medical oncologist of Jiahui International Cancer Center, graduated from the First Affiliated Hospital of Zhengzhou University with a Master of Medicine degree (hematology) in 2013. Before joining Jiahui Health, she has worked in two hematonosis hospitals. During 6 years of clinical practice, she has accumulated experience in advanced hematology oncology treatments such as allogeneic hematopoietic stem cell transplantation and CAR-T. Dr. Feng specializes in the treatment of common benign and malignant hematological diseases such as leukemia, lymphoma, myelodysplastic syndrome and aplastic anemia, including allogeneic hematopoietic stem cell transplantation techniques and CAR-T techniques.

      Read More

      SHAO Yilin, MD, PhD

      Department:
      Medical Oncology
      Palliative Care
      Medical Oncology(Solid Tumor)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. SHAO Yilin is currently an oncologist at Jiahui International Cancer Center. Dr. Shao graduated from Shanghai Medical College Fudan University (8-year program in clinical medicine) with a Ph.D. in oncology. She was granted the outstanding graduate of Fudan University. Before joining Jiahui Health, Dr. Shao completed her standardized training of residents at Fudan University Shanghai Cancer Center and then worked at the Cancer Centre of Shanghai Tenth People’s Hospital. Dr. Shao has several years of clinical experience in medical oncology, especially in diagnosis and treatment of breast cancer and other common cancer. She has been involved in various clinical research projects and has published several SCI papers.

      Read More

      Volker RUDAT (External Specialist), MD,PhD

      Department:
      Jiahui International Cancer Center
      Radiation Oncology
      International Cancer Consultant
      Hepatobiliary Tumor MDT Clinic
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      English,  Deutsch
      Doctor's bio

      Dr. Volker RUDAT is the Consultant of the Department of Radiation Oncology at Jiahui International Cancer Center, and Professor of Radiation Oncology at the University Hospital Hamburg (UKE), Germany. 


      He received his scientific and clinical education at the German Cancer Research Center (dkfz) and University of Heidelberg, Germany. In 2001, he was appointed Professor and Vice Director of the Department of Radiation Oncology of the University Hospital Hamburg (UKE) and in 2006, Director of the Department of Radiation Oncology of the St. Josef University Hospital, Bochum, Germany. Dr. Rudat followed an invitation to Al Khobar, Saudi Arabia, where he and his team established a large Oncology Center. 


      Dr. Rudat has performed many clinical and radiobiological studies which are reflected in more than 100 international scientific publications. He contributed scientifically to the development of concomitant radiochemotherapy, intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT). Dr. Rudat served as a principal investigator of a German prospective multicenter study establishing larynx function preserving therapy in Germany. Apart from the radiotherapy and radiochemotherapy of head and neck cancer, his clinical and scientific interest focuses on the radiotherapy of breast cancer, prostate cancer, lung cancer, rectal cancer, and other malignant tumors and benign conditions.


      *Scientific publications Dr. Volker RUDAT

      Read More

      WANG Bin, MD,PhD

      Department:
      Jiahui International Cancer Center
      Radiation Oncology
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. WANG Bin serves as a radiation oncologist of Jiahui International Cancer Center. Dr. Wang obtained the bachelor degree of Clinical Medicine from Zhengzhou University School of Medicine in 1999, and then he received the master degree in medical oncology and Ph.D. in pathology at Shanghai Secondary Millitary University. Before joining Jiahui Health, he served as attending physician in the Center of Clinical Oncology, Shenzhen Hospital, Hong Kong University and Department of Radiation at a private cancer center in Shanghai. In 2018, he visited the Cancer Center of Queen Mary Hospital, Hong Kong University and Pamela Youde Nethersole Eastern Hospital. Being a radiation oncologist for more than ten years, he specializes in conventional radiation therapy and stereotactic radiotherapy of various tumors, especially the treatment of gastrointestinal, breast, and head & neck cancers. In addition, he also pays close attention to the cardiac toxicity during breast cancer radiotherapy.


      Dr. Wang joined as sub-investigators in a global multi-center clinical trials for liver cancer radiotherapy and a HCC basic research supported by National Natural Science Foundation of China.


      He had several academic publications. He had participated in the translation of the English version of Proton Therapy by MDACC and Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy by Nancy Y. Lee.
      Dr. Wang is a current member of Chinese Society of Clinical Oncology (CSCO).

      Read More

      YANG Fang, MD

      Department:
      Jiahui International Cancer Center
      Palliative Care
      Medical Oncology(Solid Tumor)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. YANG Fang is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a Bachelor's degree in Clinical Medicine from Harbin Medical University in 2004 and obtained a Master's degree in Oncology from Harbin Medical University in 2007. From 2012 to 2013, she has studied at the Cancer Hospital Affiliated to Fudan University and the Cancer Center of West China Hospital. In 2018, she received training in breast cancer diagnosis and treatment at Dana-Farber Cancer Center in the United States. Dr. Yang has been practiced oncology for more than fifteen years. She is very knowledgeable in diagnosing and treating a wide variety of solid tumors, including breast cancer, GYN malignancies, lung cancer, GI malignancies, etc. She is also good at palliative care for terminal cancer patients. Dr. Yang has experience working in general tier 1 hospital, tertiary cancer hospital, and international hospital. She was in charge of international consultation for complicated cancer patients. She is also licensed as a psychologist and health management. 

      Read More

      ZHANG Lihua, MD, PhD

      Department:
      Jiahui International Cancer Center
      Radiation Oncology
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English,  日本語
      Doctor's bio

      Dr. ZHANG Lihua serves as an attending physician in radiation oncology department of Jiahui International Cancer Center. Dr. Zhang completed her six-year clinical medical program in Japanese at Norman Bethune Health Science Center of Jilin University in 2003. She obtained her clinical master degree from Obstetrics & Gynecology Hospital of Fudan University and PhD degree of Oncology from Fudan University Shanghai Cancer Center. Since 2012, Dr. Zhang has received extensive training in Internal Medicine and undergone resident standardization training and specialist training in Radiotherapy at Shanghai Sixth People's Hospital. In October 2014, she visited Heidelberg University Medical School in Germany, focusing on intraoperative radiotherapy techniques for breast cancer, pancreatic cancer, and gynecological tumors. With over ten years of experience in radiation oncology department, Dr. Zhang also serves as a national instructor for resident standardization training and specialist training in radiation oncology.

      Dr. Zhang specializes in the comprehensive treatment of a wide range of cancers through radiotherapy and chemotherapy. Her expertise extends to gynecological tumors, including cervical, vaginal, and endometrial cancers; gastrointestinal tumors such as esophageal, pancreatic, stomach, intestinal, and liver cancers; head and neck tumors like nasopharyngeal, nasal sinus, ear canal, parotid gland, and gliomas; thoracic tumors including lung and thymus cancers; and urological tumors encompassing bladder, kidney, ureteral, and prostate cancers. Furthermore, Dr. Zhang is adept in treating soft tissue tumors, bone tumors, lymphomas, myelomas, breast cancer, and benign conditions such as synovitis, heterotopic ossification, and keloids with advanced radiotherapy techniques. These techniques include adaptive radiotherapy, intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), intraoperative radiation therapy (IORT), stereotactic body radiotherapy (SBRT), and brachytherapy. She is particularly experienced in using AI-assisted radiotherapy for the treatment of complex, recurrent, and metastatic tumors, and re-irradiation, especially in brachytherapy for gynecological tumors.

      Dr. Zhang has published dozens of articles in Chinese and English, primarily involved in three projects at the directorate and municipal science committee level related to cervical cancer and esophageal cancer. Currently, she is a member of the youth committee of radiotherapy branch of the Shanghai Medical Association, and a member of the youth radiotherapy committee of the Shanghai Anti-Cancer Association.

      Read More

      XU Rong, MD

      Department:
      Jiahui International Cancer Center
      Palliative Care
      Hematology
      Medical Oncology (Hematology)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English
      Doctor's bio

      Dr. XU Rong serves as an attending physician in medical oncology department of Jiahui International Cancer Center. Dr. Xu got her Bachelor’s Degree in Clinical Medicine in 2003 and Medical Master’s Degree in Hematology in 2007 from Shanghai Jiaotong University School of Medicine. From 2007 to 2017, Dr. Xu worked in the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Before joining Jiahui, Dr. Xu was in charge of the HSCT unit in a hematology hospital, specializing in autologous and allogeneic hematopoietic stem cell transplantation and CAR-T cell therapy for relapsed and refractory hematologic tumors. She is adept at managing complications in allogeneic hematopoietic stem cell transplantation, treating post allogeneic HSCT problems such as GVHD, infections, primary and secondary graft failure, thrombotic complications, tumor relapse, etc. Dr. Xu also has extensive experience in autologous hematopoietic stem cell transplantation for multiple myeloma and lymphoma, and CAR-T cell therapy including auto-HSCT bridging CAR-T, tandem CAR-T, double-target CAR-T. Dr. Xu has mastered the technology of invasive and non-invasive mechanical ventilation, continuous renal replacement therapy, hemodynamic monitoring, and intensive rehabilitation techniques. Dr. Xu is qualified in internal medicine, critical care medicine and rehabilitation medicine. As for academic field, she has published more than ten Chinese core journal articles and two SCI papers.

      Read More

      XUE Peng, MD, PhD

      Department:
      Jiahui International Cancer Center
      Palliative Care
      Medical Oncology(Solid Tumor)
      Location:
      Jiahui International Hospital (Shanghai)
      Languages:
      普通话,  English,  日本語
      Doctor's bio

      Dr. XUE Peng is an oncologist at Jiahui international cancer center major in solid tumor. He graduated from Shanghai Second Medical University with Bachelor degree in 2000. And he had three years of research experience in state key laboratory of oncogenes & related genes at Shanghai Cancer Institute from 2000 to 2003. Then he achieved Master degree in clinical oncology at Shanghai Jiaotong University School of medicine in 2006. Before joining Jiahui Health, he has served as an attending physician in the oncology department of Shanghai General Hospital since 2006. And he obtained the Ph.D. in clinical oncology during the work. He received academic funding of Sasagawa fellowship to participate medical research in Kyoto University Hospital in Japan from 2012 to 2013.


      Dr. Xue specializes in diagnosis and treatment of solid tumor, especially gastrointestinal cancer, pancreatic cancer, breast cancer, lung cancer etc. He had published several peer-reviewed paper in the field of chemotherapy for pancreatic cancer patients.


      Now Dr. Xue is a member of Chinese Society of Clinical Oncology and Japan-china Medical Association.

      Read More

    CONTACT US

    Follow us

    Jiahui's Partners

    Copyright © 2017 by Jiahui,Inc. All rights reserved 沪ICP备15019023号-1 | 沪公网安备 31010402004841 号

    2021-06-01
    • Scan the QR code to follow
      Expat account Jiahui Health